About this trial
Objectives: To evaluate the efficacy of topical tranexamic acid applied on the placental bed after placental delivery to reduce blood loss during cesarean delivery in women with placenta previa.
Patients will be randomly assigned into two groups:
Group (A) - Study group (n=28): The topical tranexamic acid group will receive topical tranexamic acid after placental delivery applied on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%, in addition to the IV infusion of 1g tranexamic acid (2 ampules 500ug) diluted with 20ml of 5% glucose administered just after delivery of the fetus.
Group (B) - Control group (n=28): The intravenous tranexamic acid group will receive only an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.
Eligibility criteria
Qualifiers
Age: 20-40 years old.
BMI less than 30 kg/m2.
Pregnancy of singleton living fetus.
Placenta previa by ultrasound assessment
Disqualifiers
Women with a history of any medical disorder with pregnancy, e.g., Gestational diabetes and hypertension.
Women with systemic diseases, e.g., diabetes mellites, systemic immune disorders such as systemic lupus erythematosus
Women with bleeding tendency or coagulopathy.
Women on anticoagulants or hemodynamically unstable women.
Trial design
Treatments tested in this trial
- Topical tranexamic acid
- Intravenous tranexamic acid